Targeting IL-13 With Tralokinumab Normalizes Type 2 Inflammation in Atopic Dermatitis Both Early & at 2 Years
Time: 11:15 am
day: Day One Clinical Track AM
Details:
- Evaluation of skin and serum biomarkers from patients enrolled in the Phase 3 ECZTRA 1 trial and long-term extension ECZTEND trials with Tralokinumab (IL-13 neutralizing monoclonal antibody)
- Gene expression assessed by RNA sequencing and protein expression assessed by immunohistochemistry and immunoassay
- Measuring Tralokinumab treatment’s improvement of epidermal pathology, along with reducing systemic markets of Type 2 inflammation and shifting expression of AD biomarkers to nonlesional levels to highlight the key role of IL-13 in AD pathogenesis
